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Abstract During the course of brain injury and inflammation 
there is an increased secretion of neurotrophic substances by 
astrocytes. We have examined the effect of the Th2-derived 
cytokine IL-10 and the Thl-derived cytokines II-2 and IFN-y on 
the secretion of NGF by mouse astrocytes. IL-10 induced a dose- 
dependent increase in NGF secretion which was blocked by anti- 
IL-10 antibody. In contrast, the Thl-derived cytokines IFNqf 
and IL-2 did not induce NGF synthesis. Moreover, INFqt 
completely inhibited the increase in NGF secretion induced by 
IL-10 whereas it had no effect on the induction of NGF by TNF- 
a. These results indicate that IL-10 similarly to other Th2- 
derived eytokines may provide a nenrotrophic support to injured 
neurons via the induction of NGF synthesis, whereas the Thl- 
derived cytokine IFN- 7 antagonizes this effect. 
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1. Introduction 
Pathological condit ions in the brain lead to activation of 
astrocytes and microglia cells in the vicinity of the insult [1]. 
These cells, as well as various lymphoid cells which infiltrate 
the CNS, secrete a large number  of cytokines which then act 
on glial and neuronal  cells [2]. Reactive astrocytes are also 
known to synthesize and secrete neurotrophic factors such 
as NGF [1] which play a role in the survival, growth and 
differentiation of CNS neurons [3]. Induct ion of NGF syn- 
thesis occurs following brain injury [4] and in response to a 
variety of cytokines such as FGF,  IL-113, TNF-c~ [5] and the 
Th2-derived cytokines IL-4 and IL-5 [6,7]. 
IL-10 is another Th2-derived factor which was originally 
identified as a factor which inhibits cytokine synthesis by 
Th l  clones [8]. IL-10 is produced by T cells, B cells and 
monocytes and it induces DNA replication and Ig secretion 
in antigen and anti-CD40 activated B cells [9]. In addition, IL- 
l0 has been reported to enhance the expression of MHC class 
II [10] and the proliferation of T cells in the presence of IL-2 
and IL-4 [11]. IL-10 has been also considered as a negative 
regulator of immune system activation due to its ability to 
inhibit cytokine product ion and IFN-7-induced MHC class 
II expression [12] and iNOS induction by IFN-  7 [13]. These 
observations implicate IL-10 as a negative regulator of im- 
mune system activation. 
In the CNS, 1L-10 mRNA has been demonstrated in mice 
recovered from experimental auto immune ncephalomyelitis 
[14], during Listeria meningitis [15] and in acute Sindbis 
virus-induced encephalitis [16]. In addition, IL-10 and its re- 
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ceptor are expressed by microglia and astrocytes [17]. In this 
study we examined the effects of the IL-10 and the Thl -de-  
rived cytokines, IL-2 and IFN-  7 on the secretion of NGF by 
astrocytes. 
2. Materials and methods 
IL-10 and neutralizing anti-ILl0 antibody, IL-2, TNF-c~ and IFN-7 
were purchased from Genzyme. Monoclonal anti-NGF and monoclo- 
hal anti-NGF conjugated to 13-galactosidase were obtained from 
Boehringer Mannheim and polyclonal anti-rabbit NGF was pur- 
chased from Sigma. 
2.1. Cell cultures 
Primary glial cultures were obtained from cerebral cortices of 2-day 
old newborn mice as previously described [18]. Under culture condi- 
tions, neurons and oligodendrocytes were eliminated and the culture 
consisted of 95% astroglia cells as determined by GFAP staining. 
2.2. NGF assay 
For the determination of NGF secretion, astrocytes (2x 106 cells/ 
ml) were incubated with the appropriate treatments and supernatants 
were collected every 24 h. NGF levels were assayed using a two-site 
enzyme-linked immunoabsorbent assay as already described [7]. The 
detection limit of this assay was about 5 pg/ml. 
2.3. Intracellular cell staining 
Cells were stimulated for 16 h with IL-10 (25 ng/ml) in the presence 
of 0.3 ~tM monensin. Intracellular staining for NGF was performed 
according to a modification of the method described by Jung et al. 
[19]. Briefly, cells (5 × 10S/ml) were washed with HBSS and fixed in 
ice-cold HBSS containing 4% paraformaldehyde (PFA) for 10 min. 
After two washes in HBSS, cells were suspended. Cells were fixed in 
methanol for 10 min at 0°C. Following blocking, cells were resus- 
pended in 300 lal of staining buffer (HBSS including 0.1% saponin, 
3%, BSA and 0.01 M HEPES buffer). After 20 min incubation cells 
were spun down and incubated with rabbit anti-NGF antibody for 30 
min followed by incubation with FITC-conjugated goat anti-rabbit 
antibody diluted in staining buffer. After washings, cells were ana- 
lyzed with a FACSscan analyzer and values of % positive cells and 
mean fluorescence intensity (MFI) were calculated. For calculating 
non-specific binding, cells were incubated with rabbit control antibod- 
ies. 
2.4. Protein assay 
Protein content of the cells was determined according to the method 
of Lowry et al. [20] using bovine serum albumin as a standard. 
2.5. Statistical analyses 
All data were analyzed using Student's t-test for comparison of the 
means. 
3. Results 
3.1. IL-IO increases NGF secretion 
For  measuring secreted NGF,  cells were treated for the 
indicated times with various concentrat ions of IL-10 in the 
presence and absence of anti-IL-10 antibody. Control  un- 
treated cells produced low amounts of NGF.  Treatment of 
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the cells with IL-10 induced a dose-dependent increase in 
NGF production. No changes in the amount of secreted 
NGF were observed in cells treated with low concentrations 
of IL-10 (1 ng/ml), however, an increase of 45% was observed 
with 5 ng/ml IL-10 and a maximal increase of 160% was 
obtained with a concentration of 25 ng/ml (Fig. 1A). The 
induction of NGF by IL-10 was inhibited by addition of 
anti-IL-10 antibody. The time course of IL-10 effect was mon- 
itored over the 72 h culture period and supernatants were 
sampled every 24 h. The effect of IL-10 was already observed 
after 24 h and plateau levels were obtained after 48 h (Fig. 
IB). The effect of IL-10 on NGF induction was not associated 
with cell proliferation since IL-10 did not increase this param- 
eter but rather exerted a small decrease (data not shown). 
3.2. IL-IO increases intracellular staining for NGF 
To study the effects of IL-10 on NGF synthesis we per- 
formed intracellular staining of NGF.  Since the effect of IL- 
l0 on NGF secretion was first observed after 24 h, we stained 
the cells 16 h following treatment with the cytokine. As can be 
seen in Fig. 2, NGF was synthesized by the majority of the 
astrocytes except for a small subpopulation of the cells (15%). 
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Fig. 1. Effects of IL-10 on NGF secretion. Dose response (A) and 
kinetics (B) of IL-10 induced NGF secretion in cortical astroglial 
cells. Cells were incubated with various concentrations of IL-10 for 
48 h in the presence or absence of anti-IL-10 (A) or in the presence 
or absence of IL-10 (25 ng/ml) for various periods of time (B). 
NGF secretion was determined by EIA. Results represent he 
means + S.D. of five separate xperiments. *p < 0.002 **p < 0.001. 
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Fig. 2. Cytofluorometric analysis of NGF in IL-10-treated astro- 
cytes. Cells were treated in the presence or absence of IL-10 (25 ng/ 
ml) for 16 h in the presence of monensin (30 riM). Cells were fixed 
with 4°/,, PFA, permeabilized with 0.1% saponin and stained with 
anti-NGF antibody. Fluorescence was quantified on a FACS ana- 
lyzer and values of % positive cells and mean fluorescence intensity 
were calculated for each histogram. Histograms of a representative 
experiment out of four are presented. 
Using intracellular staining for GFAP  it appeared that this 
population of cells was characterized by low levels of GFAP  
(data not shown). Treatment of the cells with IL-10 increased 
the amount of NGF produced by the cells as determined by 
mean fluorescence values (MFI). Thus, MF I  values for con- 
trol cells was 76.8, whereas that of IL-10-treated cells in- 
creased to 158. 
3.3. The Thl-derived cytokines, 1L-2 and IFN-7 do not increase 
NGF secretion 
Based on recent reports and on our current findings it ap- 
pears that the Th2-derived cytokines IL-5, IL-4 and IL-10 
increase NGF production by astrocytes. We therefore xam- 
ined the effects of the Thl-derived cytokines, IFN-  7 and IL-2 
on NGF production. Cells treated with IL-2 (10 100 U/ml) or 
with IFN- 7 (10 100 U/ml) up to 72 h did not increase NGF 
production. Moreover, IFN- 7 at concentration over 50 U/ml 
inhibited the basal levels of NGF production by 35% (data 
not shown). 
3.4. IFN7 inhibits IL-IO induced NGF secretion 
IL-10 and IFN- 7 have been shown to exert antagonistic 
effects on various functions of lymphoid cells [12,13]. We 
therefore xamined the interaction of these two cytokines on 
NGF production. Cells were treated concomitantly with IL-10 
and IFN- 7 and supernatants were analyzed for NGF levels. 
IFN-  7 at a concentration of 50 U/ml inhibited NGF produc- 
tion by 20%. Concomitant reatment of IL-10 and IFN-y in- 
hibited NGF secretion by 75% (Fig. 3A) whereas pre-treat- 
ment of the cells with IFN-7 exerted stronger inhibition of 
NGF production induced by IL-10 (87%). Similar effects 
were obtained with the production of NGF by IL-4-treated 
cells (data not shown). 
In contrast, IFN-y did not inhibit the production of NGF 
induced by another cytokine, TNF-cc Thus, treatment of the 
cells with IFN- 7 either concomitantly with or prior to TNF-c~ 
did not induce significant inhibition in NGF production (Fig. 
3B). 
4. Discussion 
Astrocytes are known to exert distinctive neurotrophic ef- 
fects which are considered to be mediated by cell surface 
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Fig. 3. Effect of combined treatment with IFN-y and IL-10 or 
TNF-c¢ on NGF secretion. Effects of combined treatments of IL-10 
and 1FN-y (A) or TNF-~x and IFN-y (B) on NGF secretion. Cells 
were incubated for 48 h with the indicated treatments and NGF se- 
cretion was determined by EIA. Results represent the means + S.D. 
of three separate xperiments. *p < 0.001, **p < 0.005. 
molecules, the extracellular matrix and by neurotrophic fac- 
tors such as NGF [21]. NGF synthesis i  induced in various 
pathological instances in the CNS such as hypoxic injury [22] 
fimbria-fornix lesions [23], and seizures [24]. In addition, stud- 
ies of signals involved in the regulation of NGF synthesis have 
shown that inflammatory stimuli contribute significantly to 
increased NGF synthesis [25]. Indeed, cytokines such as 
TNF-cx [26], IL-1, IL-6 and TGF-~ [27] increase NGF syn- 
thesis in peripheral tissues and in rat cortical astrocytes. 
Moreover, in a recent study Bracci-Laudiero et al. [28] found 
a correlation between NGF levels in the CSF of patients with 
multiple sclerosis and the stage of the disease. 
We found that IL-10 induced NGF synthesis/secretion in 
cortical astrocytes. These results are similar to those reported 
for other Th2-derived cytokines, IL-4 and IL-5 [6,7]. IL-10 
can be produced by either activated astrocytes and microglia 
[17] or by peripheral lymphoid cells which infiltrate the CNS. 
Indeed, IL-10 has been associated with pathological instances 
in the CNS including experimental utoimmune encephalitis 
[14], Listeria meningitis [15] and acute Sindbis virus-induced 
encephalitis [16]. 
The significance of the IL-10 effect on NGF secretion 
should be considered in view of the possible roles which 
Th2-derived cytokines play in the CNS during pathological 
conditions. It has been suggested that the expression of 
type-2 cytokines in the CNS increases antibody production, 
decreases cell-mediated immunity and therefore reduces the 
development of inflammation and neuropathology [16]. The 
ability of IL-10 as well as other Th2-derived cytokines to 
increase NGF synthesis may contribute to the increased neu- 
ronal support and reduced neurotoxicity associated with type- 
2 response in the CNS. Moreover, NGF has been shown to 
induce proliferation and immunoglobulin secretion by B lym- 
phocytes via functional receptors [29,30]. Thus, the increased 
synthesis/secretion of NGF by Th2-derived cytokines can also 
contribute to the B-cell derived antibody response by acting 
directly on these cells. 
In contrast o IL-10 effects, Thl-derived cytokines uch as 
IL-2 and IFN-y did not induce NGF secretion. Moreover, 
IFN-y reduced the basal level of NGF secreted by astrocytes 
and completely inhibited NGF synthesis induced by IL-10 
whereas it did not inhibit the effect of TNF-c~. Inhibitory 
effects of IFN-y on NGF secretion were reported by Awatsuji 
et al. [6] and were associated with the antiproliferative effect 
of IFN-y. The effects of both IL-10 and IFN-y on NGF secre- 
tion in our cells cannot be attributed to cell proliferation since 
both cytokines were used in concentrations that did not in- 
duce significant changes in astrocyte proliferation. 
Our results suggest antagonistic effects of Thl and Th-2 
derived cytokines on NGF synthesis by astrocytes. Indeed, 
these two subsets of CD4 T cells are functionally distinct 
and frequently act in an antagonistic manner, a factor which 
determines the outcome of some infectious and autoimmune 
diseases [31,32]. In the CNS, astrocytes and microglia ppear 
to express functional receptors to these cytokines [7,17,33,34] 
and similar antagonistic interactions have also been shown to 
exist in these cells. Thus, IL-4 antagonizes the induction of 
NO production by IFN-y in microglia cells [35] and both 1L-4 
and IL-10 inhibits the expression of MHC class II in these 
cells [36]. Similarly, IL-10 suppresses the MHC class II and 
Ag-dependent proliferative response of T cells in the presence 
of APC [37]. 
Inflammatory processes in the CNS are associated with a 
variety of pathological conditions uch as traumatic injury, 
ischemia, AIDS related dementia and Alzheimer's disease 
[38] thus emphasizing the importance of understanding the 
mechanisms of this response and its contribution to exacerba- 
tion or recovery of tissue injury. Our results indicate that the 
induction of NGF by IL-10 may be an important component 
in the function of Th2-derived cytokines as suppressors of 
inflammation and neurotoxicity. 
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